In this episode of Nurse Rosa’s INsights, host Rosa Hart speaks with Dr. Selin Kurnaz, CEO and co-founder of MassiveBio, and Craig Lipset, a globally recognized expert in decentralized clinical trials. Together, they discuss how artificial intelligence and technology are transforming patient access to clinical research and reshaping the future of healthcare innovation. Their conversation explores how decentralized trials expand access for patients within their own communities as well as globally, the importance of patient engagement in successful research, and the critical role of trust and communication between patients and healthcare providers. They also address the barriers that keep patients unaware of available trials, the challenges of navigating the patient journey, and the need for new funding models to advance rare disease research. Key takeaways include that AI and technology can dramatically reduce the time required to match patients with the right trials, while patient engagement and trust remain essential for participation. Decentralized trials open opportunities for more diverse populations, and simplifying the patient journey helps make research more accessible. Transparent data sharing empowers patients and improves outcomes, and innovative funding strategies are vital to support research for rare diseases. Ultimately, healthcare systems must evolve to better support participation in clinical trials, and collaboration among researchers, clinicians, and patients is the key to driving meaningful progress. Connect with Craig Lipset on LinkedIN Learn more about the Buffalo Initiative Connect with Dr. Selin Kurnaz on LinkedIN Visit MassiveBio.com Follow Nurse Rosa’s INsights and leave a review for more conversations at the intersection of nursing, innovation, and patient empowerment. Visit NurseRosaSpeaks.com for resources and upcoming episodes. For more podcasts hosted by Rosa Hart, tune in to "Stronger After Stroke", "Aging Like A Pro" and "The Lou Review".